Chinese Biotech Firms Embrace Licensing Model as Out-Licensing Deals Hit Record High
On.cc · 1 SOURCESabout 2 hours ago2 MIN
Summary
Chinese innovative drug companies are undergoing a profound structural transformation as they shift away from building their own sales teams toward licensing overseas rights to multinational pharmaceutical giants. According to data from China's National Medical Products Administration, 81 out-licensing deals were completed in the first half of 2026, with a total transaction value of approximately US$110 billion—already reaching 80% of the full-year 2025 figure. This licensing revenue has evolved from a supplementary income source to a decisive factor in turning unprofitable biotech firms toward profitability.
Key Points
- China's National Medical Products Administration recorded 81 out-licensing deals in H1 2026, with total deal value around US$110 billion
- Total upfront payments reached approximately US$5 billion in the first six months, accounting for roughly 70% of 2025's annual total
- Average upfront payment for business development deals climbed to US$60 million, representing a 38% year-on-year increase
- Average transaction size rose to US$1.06 billion, up 22% year-on-year, with payment structure including upfront, milestone, and royalty components
- The industry's value chain is transitioning from selling products to selling pipelines, and from self-built sales to R&D-driven models
Why It Matters
This licensing wave signals a fundamental reshaping of how Chinese biotech companies generate value and attract capital, shifting from traditional pharmaceutical revenue models to asset-light strategies that could redefine industry valuation metrics for Hong Kong investors and market watchers alike .
This licensing wave signals a fundamental reshaping of how Chinese biotech companies generate value and attract capital, shifting from traditional pharmaceutical revenue models to asset-light strategies that could redefine industry valuation metrics for Hong Kong investors and market watchers alike .